Q-omics provides the consensus-scored TRO profile across patient tissues and cancer cell-line models. TRO expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, TRO is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, TRO RNA expression shows 19,482 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCS, KICH, and GBM as cancer lineages where TRO shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRO — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRO survival associations across molecular data types. TRO RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRO RNA expression–survival associations across cancer types. High TRO expression shows unfavorable associations in STAD, MESO, BLCA and UCEC, but favorable associations in UCS and PAAD. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify UCS as the clearest survival context for TRO RNA expression.
This table summarizes TRO tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for TRO. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRO shows lower tumor expression in KICH, THCA, UCEC, BRCA and KIRC and higher tumor expression in LUSC. The KICH box plot shows higher TRO RNA expression in normal versus tumor tissue (log2 FC = −2.321, t-test p < 0.001).
This table shows molecular features associated with TRO in patient tissues and cancer cell lines. In patient samples, TRO shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRO RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
